{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:38:54Z","timestamp":1792719534009,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.diabres.2026.113605","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:40:59Z","timestamp":1791960059000},"page":"113605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dapagliflozin and 54-week kidney function in kidney transplant recipients with post-transplant diabetes mellitus: a randomized controlled trial"],"prefix":"10.1016","volume":"242","author":[{"given":"Jinghui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongkun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqian","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.diabres.2026.113605_b0005","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1034\/j.1600-6143.2003.00010.x","article-title":"Diabetes mellitus after kidney transplantation in the United States","volume":"3","author":"Kasiske","year":"2003","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.diabres.2026.113605_b0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/ndt\/gfad258","article-title":"International consensus on post-transplantation diabetes mellitus","volume":"39","author":"Sharif","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.diabres.2026.113605_b0015","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ecl.2007.07.007","article-title":"New onset diabetes mellitus after solid organ transplantation","volume":"36","author":"Pham","year":"2007","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"24","key":"10.1016\/j.diabres.2026.113605_b0020","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.diabres.2026.113605_b0025","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2026.113605_b0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113605_b0035","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","article-title":"A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors","volume":"33","author":"Sen","year":"2021","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.diabres.2026.113605_b0040","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.diabres.2026.113605_b0045","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","article-title":"The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients","volume":"106","author":"Lim","year":"2022","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.diabres.2026.113605_b0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5500\/wjt.v13.i5.239","article-title":"Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients","volume":"13","author":"Ramakrishnan","year":"2023","journal-title":"World J Transplant"},{"issue":"9","key":"10.1016\/j.diabres.2026.113605_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100697","article-title":"SGLT2 inhibitors in management of severe hypomagnesemia in patients without diabetes: a report of 4 cases","volume":"5","author":"Shah","year":"2023","journal-title":"Kidney Med"},{"issue":"5","key":"10.1016\/j.diabres.2026.113605_b0060","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1053\/j.ajkd.2023.11.006","article-title":"Sodium\/glucose cotransporter 2 inhibitors and magnesium homeostasis: a review","volume":"83","author":"Shah","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"10.1016\/j.diabres.2026.113605_b0065","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin c-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113605_b0070","doi-asserted-by":"crossref","unstructured":"Kidney disease: improving global outcomes (KDIGO) diabetes work group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1-S127. doi:10.1016\/j.kint.2022.06.008.","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"10.1016\/j.diabres.2026.113605_b0075","doi-asserted-by":"crossref","unstructured":"Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016\/j.kint.2023.10.018.","DOI":"10.1016\/j.kint.2023.10.018"},{"issue":"5","key":"10.1016\/j.diabres.2026.113605_b0080","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.diabres.2026.113605_b0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.diabres.2026.113605_b0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.diabres.2026.113605_b0110","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/ijn.IJN_2_18","article-title":"Efficacy and safety of canagliflozin in kidney transplant patients","volume":"29","author":"Shah","year":"2019","journal-title":"Indian J Nephrol"},{"issue":"2","key":"10.1016\/j.diabres.2026.113605_b0115","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.185","article-title":"Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients","volume":"4","author":"Song","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.diabres.2026.113605_b0120","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221090001","article-title":"Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?","volume":"13","author":"Ujjawal","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.diabres.2026.113605_b0125","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/ckj\/sfad007","article-title":"Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study","volume":"16","author":"S\u00e1nchez Fructuoso","year":"2023","journal-title":"Clin Kidney J"},{"issue":"11","key":"10.1016\/j.diabres.2026.113605_b0130","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1007\/s11255-023-03645-7","article-title":"The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers","volume":"55","author":"Demir","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.diabres.2026.113605_b0135","doi-asserted-by":"crossref","first-page":"12879","DOI":"10.3389\/ti.2024.12879","article-title":"SGLT2 inhibitors correct fluid overload in adult kidney transplant recipients-a prospective observational study","volume":"37","author":"Schork","year":"2024","journal-title":"Transpl Int"},{"issue":"1","key":"10.1016\/j.diabres.2026.113605_b0140","doi-asserted-by":"crossref","first-page":"10043","DOI":"10.1038\/s41467-024-54171-8","article-title":"The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients","volume":"15","author":"Sheu","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.diabres.2026.113605_b0145","article-title":"Safety of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with diabetes mellitus","volume":"51","author":"Diker Cohen","year":"2025","journal-title":"Diabetes Metab"},{"issue":"20","key":"10.1016\/j.diabres.2026.113605_b0150","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.3390\/jcm13206181","article-title":"Safety and efficacy of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney transplant recipients: synthesis of evidence","volume":"13","author":"Bellos","year":"2024","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.diabres.2026.113605_b0155","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.diabres.2026.113605_b0160","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.trre.2015.05.002","article-title":"Hypomagnesaemia in kidney transplantation","volume":"29","author":"Van Laecke","year":"2015","journal-title":"Transplant Rev (Orlando)"},{"issue":"7","key":"10.1016\/j.diabres.2026.113605_b0165","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.3390\/ijms26072904","article-title":"Impact of SGLT2 inhibitors on magnesium in kidney transplant patients with and without diabetes","volume":"26","author":"Secondulfo","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.diabres.2026.113605_b0170","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/ndt\/gfaf046","article-title":"Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease","volume":"40","author":"Bakker","year":"2025","journal-title":"Nephrol Dial Transplant"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726005255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726005255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:19:31Z","timestamp":1792718371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726005255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":31,"alternative-id":["S0168822726005255"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113605","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin and 54-week kidney function in kidney transplant recipients with post-transplant diabetes mellitus: a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113605"}}